Patient demographics and baseline characteristics
| Demographics and baseline characteristics . | PTCL (n = 16) . | CTCL (n = 19) . | All TCL (n = 35) . |
|---|---|---|---|
| Demographics | |||
| Age (y), median (range) | 70 (34-86) | 64 (48-81) | 64 (34-86) |
| Sex, male, n (%) | 8 (50) | 8 (42) | 16 (46) |
| Baseline disease status | |||
| Baseline disease stage, n (%) | Stage IE: 1 (6) | Stage IB: 5 (26) | ≥Stage III: 25 (71) |
| Stage III: 5 (31) | Stage II, IIB: 4 (21) | ||
| Stage IV: 10 (63) | Stage III, IIIA: 3 (16) | ||
| Stage IV, IVA: 7 (37) | |||
| Eastern Cooperative Oncology Group score, 0 /1/2 | 6%/69%/25% | 21%/68%/11% | 14%/69%/17% |
| No. of prior systemic therapies, median (range) | 2.5 (1-7) | 6 (2-10) | 4 (1-10) |
| Years from initial diagnosis, median (range) | 2.9 (0.6-8.9) | 5.1 (0.4-24.9) | 4.1 (0.4-24.9) |
| Months from most recent systemic therapy, median (range) | 1.7 (0.4-24.8) | 0.8 (0.2-2.9) | 1.1 (0.2-24.8) |
| International Prognostic Index score (poor, 3-5 factors), n (%) | 10 (63) | 8 (42) | 18 (51) |
| Demographics and baseline characteristics . | PTCL (n = 16) . | CTCL (n = 19) . | All TCL (n = 35) . |
|---|---|---|---|
| Demographics | |||
| Age (y), median (range) | 70 (34-86) | 64 (48-81) | 64 (34-86) |
| Sex, male, n (%) | 8 (50) | 8 (42) | 16 (46) |
| Baseline disease status | |||
| Baseline disease stage, n (%) | Stage IE: 1 (6) | Stage IB: 5 (26) | ≥Stage III: 25 (71) |
| Stage III: 5 (31) | Stage II, IIB: 4 (21) | ||
| Stage IV: 10 (63) | Stage III, IIIA: 3 (16) | ||
| Stage IV, IVA: 7 (37) | |||
| Eastern Cooperative Oncology Group score, 0 /1/2 | 6%/69%/25% | 21%/68%/11% | 14%/69%/17% |
| No. of prior systemic therapies, median (range) | 2.5 (1-7) | 6 (2-10) | 4 (1-10) |
| Years from initial diagnosis, median (range) | 2.9 (0.6-8.9) | 5.1 (0.4-24.9) | 4.1 (0.4-24.9) |
| Months from most recent systemic therapy, median (range) | 1.7 (0.4-24.8) | 0.8 (0.2-2.9) | 1.1 (0.2-24.8) |
| International Prognostic Index score (poor, 3-5 factors), n (%) | 10 (63) | 8 (42) | 18 (51) |